AMENDMENT NO. 4 TO SC 13G

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

 

 

 

 

 

Incara Pharmaceuticals Corporation


(Name of Issuer)

 

 

Common Stock


(Title of Class of Securities)

 

 

45324E103


                                (CUSIP Numbers)                                

 

 

October 28, 2003


(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)

 

¨ Rule 13d-1(c)

 

x Rule 13d-1(d)

 

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



  1.  

Name of Reporting Person

I.R.S. Identification No. of above persons (entities only)

 

            Clayton I. Duncan

   

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ¨

            Not Applicable                                                                                                                                                        (b)  ¨

   

  3.  

SEC Use Only

 

   

  4.  

Citizenship or Place of Organization

 

            United States

   

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

  5.    Sole Voting Power

 

                1,551,475


  6.    Shared Voting Power

 

                0


  7.    Sole Dispositive Power

 

                1,551,475


  8.    Shared Dispositive Power

 

                0


  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

            1,551,475

   

10.  

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

            Not Applicable

   

11.  

Percent of Class Represented by Amount in Row (9)

 

            10.4%

   

12.  

Type of Reporting Person (See Instructions)

 

            IN

   


Item 1(a)

  

Name of Issuer

 

Incara Pharmaceuticals Corporation

         

Item 1(b)

   Address of Issuer’s Principal Executive Offices          
    

79 T.W. Alexander Dr., 4401 Research Commons, Suite 200, P.O. Box 14287,

Research Triangle Park, NC 27709-4287

         

Item 2(a)

  

Name of Person Filing

 

Clayton I. Duncan

         

Item 2(b)

  

Address of Principal Business Office

 

79 T.W. Alexander Dr., 4401 Research Commons, Suite 200, P.O. Box 14287,

Research Triangle Park, NC 27709-4287

         

Item 2(c)

  

Citizenship

 

UnitedStates

         

Item 2(d)

   Title of Class of Securities          
     Common Stock          

Item 2(e)

  

CUSIP Number    

 

45324E103

         

Item 3    

   Filing Pursuant to Rules 13d-1(b) or 13d-2(b)     
          Not Applicable.          

Item 4

   Ownership          
     (a)    As of October 28, 2003, Mr. Duncan beneficially owned an aggregate of 1,551,475 shares of the Issuer’s Common Stock which includes (i) 482,470 shares owned (of which, 84,444 shares are unvested shares of restricted stock) by Mr. Duncan, (ii) 192,000 shares owned by Mr. Duncan’s children, (iii) 102,700 shares owned by a family LLC, (iv) 759,425 shares issuable upon exercise of options held by Mr. Duncan and (v) 14,880 shares issuable upon exercise of warrants held by the family LLC. Mr. Duncan disclaims beneficial ownership of the shares held by his children.          


     (b)   

Percent of Class:

 

10.4%

         
     (c)    Number of shares as to which such person has:          
          (i)    Sole power to vote or to direct the vote: 1,551,475          
          (ii)    Shared power to vote or to direct the vote: 0          
          (iii)    Sole power to dispose or to direct the disposition of: 1,551,475          
          (iv)    Shared power to dispose or to direct the disposition of: 0          

Item 5

   Ownership of Five Percent or Less of a Class     
         

Not Applicable

Item 6

   Ownership of More than Five Percent on Behalf of Another Person          
         

Not Applicable.

         

Item 7

   Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company
         

Not Applicable

         

Item 8

   Identification and Classification of Members of the Group          
         

Not Applicable

         

Item 9

   Notice of Dissolution of Group          

Item 10

   Certification          
         

Not Applicable

         

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

October 28, 2003

Date

/s/    Clayton I. Duncan


Clayton I. Duncan